CoChat
Sign Up
Cited by 20

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Recent developments in antibody derivatives against colorectal cancer; A review

Ghani, Sepideh, Bahrami, Samira, Rafiee, Behnam, Eyvazi, Shirin, Yarian, Fatemeh, Ahangarzadeh, Shahrzad, Khalili, Saeed, Shahzamani, Kiana, Jafarisani, Moslem, Bandehpour, Mojgan, Kazemi, Bahram·2021·Life Sciences
DOI 10.1016/j.lfs.2020.118791
Open this paper in CoChat — free account

Abstract

Colorectal cancer (CRC) is the fourth most common cause of cancer and mortality worldwide and is the third most common cancer in men and women. Surgery, radiotherapy, and chemotherapy are conventionally used for the treatment of colorectal cancer. However, these methods are associated with various side effects on normal cells. Thus, new studies are moving towards more effective and non-invasive methods for treatment of colorectal cancer. Targeted therapy of CRC is a promising new approach to enhance the efficiency and decrease the toxicity of the treatment. In targeted therapy of CRC, antibody fragments can directly inhibit tumor cell growth and proliferation. They also can act as an ideal carrier for targeted delivery of anticancer drugs. In the present study, the structure and function of different formats of antibody fragments, immune-targeted therapy of CRC using antibody fragments will be discussed.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.lfs.2020.118791

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 2 references

Research works printed but not linked: 95

  1. Araghi, 2019, Global trends in colorectal cancer mortality: projections to the year 2035, Int. J. Cancer, 144, 2992, 10.1002/ijc.32055 · DOI
  2. Sharma, 2020, An examination of colorectal cancer burden by socioeconomic status: evidence from GLOBOCAN 2018, EPMA Journal, 11, 95, 10.1007/s13167-019-00185-y · DOI
  3. Françoso, 2017, Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies, Drug design, development and therapy, 11, 177, 10.2147/DDDT.S119036 · DOI
  4. Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 68, 394
  5. Carroll, 2014, Tests and investigations for colorectal cancer screening, Clin. Biochem., 47, 921, 10.1016/j.clinbiochem.2014.04.019 · DOI
  6. Shi, 2019, An enrichment model using regular health examination data for early detection of colorectal cancer, Chin. J. Cancer Res., 31, 686, 10.21147/j.issn.1000-9604.2019.04.12 · DOI
  7. Coghlin, 2013, Progress in the identification of plasma biomarkers of colorectal cancer, Proteomics, 13, 2227, 10.1002/pmic.201300245 · DOI
  8. Hagan, 2013, Targeted therapies in colorectal cancer—an integrative view by PPPM, EPMA Journal, 4, 3, 10.1186/1878-5085-4-3 · DOI
  9. Heinemann, 2013, Targeted therapy in metastatic colorectal cancer–an example of personalised medicine in action, Cancer Treat. Rev., 39, 592, 10.1016/j.ctrv.2012.12.011 · DOI
  10. Southam, 1976, History and prospects of immunotherapy of cancer: an introduction, Ann. N. Y. Acad. Sci., 277, 1, 10.1111/j.1749-6632.1976.tb41687.x · DOI
  11. Mellman, 2011, Cancer immunotherapy comes of age, Nature, 480, 480, 10.1038/nature10673 · DOI · Paper page
  12. Decker, 2017, Cancer immunotherapy: historical perspective of a clinical revolution and emerging preclinical animal models, Front. Immunol., 8, 829, 10.3389/fimmu.2017.00829 · DOI
  13. Oiseth, 2017, Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead, Journal of Cancer Metastasis Treatment, 3, 12, 10.20517/2394-4722.2017.41 · DOI
  14. Van der Jeught, 2018, Drug resistance and new therapies in colorectal cancer, World J. Gastroenterol., 24, 3834, 10.3748/wjg.v24.i34.3834 · DOI · Paper page
  15. Tol, 2010, Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review, Clin. Ther., 32, 437, 10.1016/j.clinthera.2010.03.012 · DOI
  16. Khiavi, 2019, Recent advances in targeted therapy of colorectal cancer: impacts of monoclonal antibodies nanoconjugates, BioImpacts: BI, 9, 123, 10.15171/bi.2019.16 · DOI
  17. Alibakhshi, 2017, Targeted cancer therapy through antibody fragments-decorated nanomedicines, J. Control. Release, 268, 323, 10.1016/j.jconrel.2017.10.036 · DOI
  18. Low, 2019, The road map of cancer precision medicine with the innovation of advanced cancer detection technology and personalized immunotherapy, Jpn. J. Clin. Oncol., 49, 596, 10.1093/jjco/hyz073 · DOI
  19. Rawla, 2019, Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors, Przegla̜d Gastroenterologiczny, 14, 89
  20. Tabernero, 2018, New development strategies of immunotherapy agents for colorectal cancer, Ann. Oncol., 29, 9, 10.1093/annonc/mdy348 · DOI
  21. van den Bulk, 2019, Harnessing the immunotherapy revolution for the treatment of colorectal cancer: neo-antigens and beyond, Medicine, 98
  22. Kopetz, 2019, New therapies and insights into the changing landscape of colorectal cancer, Nat. Rev. Gastroenterol. Hepatol., 16, 79, 10.1038/s41575-018-0100-z · DOI
  23. Shapira, 2010, Targeted immunotherapy for colorectal cancer: monoclonal antibodies and immunotoxins, Expert Opin. Investig. Drugs, 19, S67, 10.1517/13543781003737668 · DOI
  24. Abakushina, 2019, Immunotherapeutic approaches for the treatment of colorectal cancer, Biochemistry-Moscow, 84, 720, 10.1134/S0006297919070046 · DOI
  25. Ciardiello, 2019, Immunotherapy of colorectal cancer: challenges for therapeutic efficacy, Cancer Treat. Rev., 76, 22, 10.1016/j.ctrv.2019.04.003 · DOI
  26. Piawah, S. and A.P. Venook, Targeted therapy for colorectal cancer metastases: a review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. Cancer.
  27. Ganesh, 2019, Immunotherapy in colorectal cancer: rationale, challenges and potential, Nat. Rev. Gastroenterol. Hepatol., 16, 361, 10.1038/s41575-019-0126-x · DOI · Paper page
  28. Gonzalez-Exposito, 2019, CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids, Journal for Immunotherapy of Cancer, 7, 10.1186/s40425-019-0575-3 · DOI
  29. Xenaki, 2017, Antibody or antibody fragments: implications for molecular imaging and targeted therapy of solid tumors, Front. Immunol., 8, 1287, 10.3389/fimmu.2017.01287 · DOI
  30. Tiernan, 2013, Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting, Br. J. Cancer, 108, 662, 10.1038/bjc.2012.605 · DOI
  31. Akamatsu, 1998, A single-chain immunotoxin against carcinoembryonic antigen that suppresses growth of colorectal carcinoma cells, Clin. Cancer Res., 4, 2825
  32. Lane, 1994, Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F (ab’) 2 antibodies, Br. J. Cancer, 70, 521, 10.1038/bjc.1994.338 · DOI
  33. Hu, 1996, Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts, Cancer Res., 56, 3055
  34. Yazaki, 2001, Tumor targeting of radiometal labeled anti-CEA recombinant T84. 66 diabody and t84. 66 minibody: comparison to radioiodinated fragments, Bioconjug. Chem., 12, 220, 10.1021/bc000092h · DOI
  35. Cai, 2007, PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84. 66 anti–carcinoembryonic antigen diabody, J. Nucl. Med., 48, 304
  36. Casey, 2002, Tumour targeting of humanised cross-linked divalent-Fab’ antibody fragments: a clinical phase I/II study, Br. J. Cancer, 86, 1401, 10.1038/sj.bjc.6600198 · DOI
  37. Lutterbuese, 2009, Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA, J. Immunother., 32, 341, 10.1097/CJI.0b013e31819b7c70 · DOI · Paper page
  38. Osada, 2010, Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody, Br. J. Cancer, 102, 124, 10.1038/sj.bjc.6605364 · DOI
  39. Rothe, 2014, The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma, Int. J. Cancer, 134, 2829, 10.1002/ijc.28609 · DOI
  40. A Baudino, 2015, Targeted cancer therapy: the next generation of cancer treatment, Current drug discovery technologies, 12, 3, 10.2174/1570163812666150602144310 · DOI
  41. Ohhara, 2016, Role of targeted therapy in metastatic colorectal cancer, World journal of gastrointestinal oncology, 8, 642, 10.4251/wjgo.v8.i9.642 · DOI
  42. Akbari, 2016, Design, expression and evaluation of a novel humanized single chain antibody against epidermal growth factor receptor (EGFR), Protein Expr. Purif., 127, 8, 10.1016/j.pep.2016.06.001 · DOI
  43. Patnaik, 2018, A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer, Cancer Chemother. Pharmacol., 82, 407, 10.1007/s00280-018-3623-7 · DOI
  44. Zalba, 2015, Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer, J. Control. Release, 210, 26, 10.1016/j.jconrel.2015.05.271 · DOI
  45. Fanali, 2014, Cancer stem cells in colorectal cancer from pathogenesis to therapy: controversies and perspectives, World J Gastroenterol: WJG, 20, 923, 10.3748/wjg.v20.i4.923 · DOI
  46. Ang, 2017, Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis, Oncotarget, 8, 10.18632/oncotarget.14592 · DOI
  47. Vallera, 2013, Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells, Cancer Biother. Radiopharm., 28, 274
  48. Schmohl, 2016, Enhanced ADCC and NK cell activation of an anticarcinoma bispecific antibody by genetic insertion of a modified IL-15 cross-linker, Mol. Ther., 24, 1312, 10.1038/mt.2016.88 · DOI
  49. Waldron, 2014, A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma, Target. Oncol., 9, 239, 10.1007/s11523-013-0290-9 · DOI
  50. Zhang, 2018, Effects of immuno-related gene polymorphisms on a bispecific antibody targeting colorectal cancer cell, Personalized medicine, 15, 167, 10.2217/pme-2017-0071 · DOI
  51. Glumac, 2018, The role of CD133 in cancer: a concise review, Clinical and translational medicine, 7, 18, 10.1186/s40169-018-0198-1 · DOI
  52. Jang, 2017, Potential mechanisms of CD133 in cancer stem cells, Life Sci., 184, 25, 10.1016/j.lfs.2017.07.008 · DOI
  53. Liou, 2019, CD133 as a regulator of cancer metastasis through the cancer stem cells, Int. J. Biochem. Cell Biol., 106, 1, 10.1016/j.biocel.2018.10.013 · DOI
  54. Barzegar Behrooz, 2019, CD133: beyond a cancer stem cell biomarker, J. Drug Target., 27, 257, 10.1080/1061186X.2018.1479756 · DOI
  55. Zhao, 2015, Targeting CD133high colorectal cancer cells in vitro and in vivo with an asymmetric bispecific antibody, J. Immunother., 38, 217, 10.1097/CJI.0000000000000086 · DOI
  56. Schmohl, 2016, Heterodimeric bispecific single chain variable fragments (scFv) killer engagers (BiKEs) enhance NK-cell activity against CD133+ colorectal cancer cells, Target. Oncol., 11, 353, 10.1007/s11523-015-0391-8 · DOI
  57. Tachezy, 2012, Activated leukocyte cell adhesion molecule (CD166)—its prognostic power for colorectal cancer patients, J. Surg. Res., 177, e15, 10.1016/j.jss.2012.02.013 · DOI
  58. Wiiger, 2010, A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth, Cancer Immunol. Immunother., 59, 1665, 10.1007/s00262-010-0892-3 · DOI
  59. Dana, 2017, Cloning and expression of the V-domain of the CD166 in prokaryotic host cell, Int. J. Cancer Ther. Oncol, 5, 10.14319
  60. Bahrami, 2020, Discovering therapeutic protein targets for muscle invasive bladder cancer by proteomic data analysis, Curr. Mol. Pharmacol., 13, 150, 10.2174/1874467212666191016124935 · DOI
  61. van Oosten, 2011, Selecting potential targetable biomarkers for imaging purposes in colorectal cancer using TArget selection criteria (TASC): a novel target identification tool, Transl. Oncol., 4, 71, 10.1593/tlo.10220 · DOI
  62. Apte, 2019, VEGF in signaling and disease: beyond discovery and development, Cell, 176, 1248, 10.1016/j.cell.2019.01.021 · DOI · Paper page
  63. Cooke, 2001, A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: receptor complex, Cancer Res., 61, 3653
  64. Smith, 2003, Isolation and characterisation of vascular endothelial growth factor-165 specific scFv fragments by phage display, Int. J. Oncol., 22, 333
  65. Miao, 2006, Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2, Biochem. Biophys. Res. Commun., 345, 438, 10.1016/j.bbrc.2006.04.119 · DOI
  66. Farajpour, 2014, A nanobody directed to a functional epitope on VEGF, as a novel strategy for cancer treatment, Biochem. Biophys. Res. Commun., 446, 132, 10.1016/j.bbrc.2014.02.069 · DOI
  67. Bendell, 2017, Final results of the McCAVE trial: a double-blind, randomized phase 2 study of vanucizumab (VAN) plus FOLFOX vs. bevacizumab (BEV) plus FOLFOX in patients (pts) with previously untreated metastatic colorectal carcinoma (mCRC), Proc. Am. Soc. Clin. Oncol., 35
  68. Jimeno, 2019, A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors, Investig. New Drugs, 37, 461, 10.1007/s10637-018-0665-y · DOI
  69. Kordi, 2018, Isolation of a novel anti-KDR3 single-chain variable fragment antibody from a phage display library, Iranian Journal of Allergy, Asthma and Immunology, 1
  70. Panjideh, 2008, Biodistribution and efficacy of [131I] A33scFv:: CDy, a recombinant antibody-enzyme protein for colon cancer, Int. J. Oncol., 32, 925
  71. Tomé-Amat, 2012, Production and characterization of scFvA33T1, an immunoRNase targeting colon cancer cells, FEBS J., 279, 3022, 10.1111/j.1742-4658.2012.08683.x · DOI
  72. Cheal, 2016, Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity 86 Y-or 177 Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates, Eur. J. Nucl. Med. Mol. Imaging, 43, 925, 10.1007/s00259-015-3254-8 · DOI
  73. Cheal, 2017, Curative multicycle radioimmunotherapy monitored by quantitative SPECT/CT-based theranostics, using bispecific antibody pretargeting strategy in colorectal cancer, J. Nucl. Med., 58, 1735, 10.2967/jnumed.117.193250 · DOI
  74. Tomé-Amat, 2015, Efficient in vivo antitumor effect of an immunotoxin based on ribotoxin α-sarcin in nude mice bearing human colorectal cancer xenografts, Springerplus, 4, 168, 10.1186/s40064-015-0943-5 · DOI
  75. Wu, 2018, Development of a tetravalent anti-GPA33/anti-CD3 bispecific antibody for colorectal cancers, Mol. Cancer Ther., 17, 2164, 10.1158/1535-7163.MCT-18-0026 · DOI
  76. Moore, 2018, Development of MGD007, a gpA33 x CD3-bispecific DART protein for T-cell immunotherapy of metastatic colorectal cancer, Mol. Cancer Ther., 17, 1761, 10.1158/1535-7163.MCT-17-1086 · DOI
  77. Organ, 2011, An overview of the c-MET signaling pathway, Therapeutic advances in medical oncology, 3, S7, 10.1177/1758834011422556 · DOI
  78. Zhang, 2018, Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities, Mol. Cancer, 17, 45, 10.1186/s12943-018-0796-y · DOI
  79. Sellmann, 2016, Balancing selectivity and efficacy of bispecific epidermal growth factor receptor (EGFR)× c-MET antibodies and antibody-drug conjugates, J. Biol. Chem., 291, 25106, 10.1074/jbc.M116.753491 · DOI
  80. Qamsari, 2017, Isolation and characterization of anti c-met single chain fragment variable (scFv) antibodies, J. Immunotoxicol., 14, 23, 10.1080/1547691X.2016.1251512 · DOI
  81. Casaletto, 2019, MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM, Proc. Natl. Acad. Sci., 116, 7533, 10.1073/pnas.1819085116 · DOI
  82. Jafari, 2018, Identification of novel single-domain antibodies against FGF7 using phage display technology, SLAS DISCOVERY: Advancing Life Sciences R&D, 23, 193, 10.1177/2472555217728520 · DOI
  83. Borek, 2018, Generation of high-affinity, internalizing anti-FGFR2 single-chain variable antibody fragment fused with Fc for targeting gastrointestinal cancers, PLoS One, 13, 10.1371/journal.pone.0192194 · DOI
  84. Tsai, 2019, Chicken-derived humanized antibody targeting a novel epitope F2pep of fibroblast growth factor receptor 2: potential cancer therapeutic agent, ACS Omega, 4, 2387, 10.1021/acsomega.8b03072 · DOI
  85. Rashidi, 2017, Targeting colorectal cancer cell lines using nanobodies; AgSK1as a potential target, Iran. J. Biotechnol., 15, 78, 10.15171/ijb.1472 · DOI
  86. Zeng, 2018, Frizzled receptors as potential therapeutic targets in human cancers, Int. J. Mol. Sci., 19, 1543, 10.3390/ijms19051543 · DOI
  87. Fazeli, 2017, Anti-proliferative effects of human anti-FZD7 single chain antibodies on colorectal cancer cells, Shiraz E-Medical Journal, 18, 10.5812/semj.45219 · DOI
  88. Coomber, 2001, Isolation of human antibodies against the central DNA binding domain of p53 from an individual with colorectal cancer using antibody phage display, Clin. Cancer Res., 7, 2802
  89. Coomber, 1999, Generation of anti-p53 Fab fragments from individuals with colorectal cancer using phage display, J. Immunol., 163, 2276, 10.4049/jimmunol.163.4.2276 · DOI
  90. Zhou, 2018, Cancer stem cells in progression of colorectal cancer, Oncotarget, 9, 33403, 10.18632/oncotarget.23607 · DOI
  91. Tarhriz, 2019, Overview of CD24 as a new molecular marker in ovarian cancer, J. Cell. Physiol., 234, 2134, 10.1002/jcp.27581 · DOI
  92. Eyvazi, 2017, Identification of a novel single chain fragment variable antibody targeting CD24-expressing cancer cells, Immunol. Lett., 190, 240, 10.1016/j.imlet.2017.08.028 · DOI
  93. Roovers, 2017, Preclinical evaluation of MCLA-158: A bispecific antibody targeting LGR5 and EGFR using patient-derived colon carcinoma organoids, AACR, 77, 32
  94. Liu, 2018, Anti-colorectal cancer effects of anti-p21Ras scFv delivered by the recombinant adenovirus KGHV500 and cytokine-induced killer cells, BMC Cancer, 18, 1087, 10.1186/s12885-018-4989-y · DOI
  95. Chi, 2016, Periplasmic expression, purification, and characterization of an anti-epidermal growth factor receptor antibody fragment in Escherichia coli, Biotechnol. Bioprocess Eng., 21, 321, 10.1007/s12257-015-0817-2 · DOI

Cited by

Sorted by citations

Metadata

Authors
Ghani, S., Bahrami, S., Rafiee, B., Eyvazi, S., Yarian, F., Ahangarzadeh, S., Khalili, S., Shahzamani, K., Jafarisani, M., Bandehpour, M., & Kazemi, B.
Venue
Life Sciences
Publisher
Elsevier BV
Published
2021-01
Volume
265
Pages
118791
ISSN
0024-3205
DOI
10.1016/j.lfs.2020.118791
Cited by
20
References
2
Language
en
Licence
Funders
Shahid Beheshti University of Medical Sciences (17047)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review